Jukemura Elisa M, Burattini Marcelo N, Pereira Carlos A P, Braga Alfésio L F, Medeiros Eduardo A S
Infectious Diseases Division, Internal Medicine Department, School of Medicine, Federal University of São Paulo, Brazil.
Braz J Infect Dis. 2007 Aug;11(4):418-22. doi: 10.1590/s1413-86702007000400010.
Potent antimicrobial agents have been developed as a response to the development of antibiotic-resistant bacteria, which especially affect patients with prolonged hospitalization in Intensive Care Units (ICU) and who had been previously treated with antimicrobials, especially third-generation cephalosporins. This study was to determine how changes in the empirical treatment of infections in ICU patients affect the incidence of Gram-negative bacteria species and their susceptibility to antimicrobials, and examine the impact of these changes on nosocomial infections. A prospective interventional study was performed in a university hospital during two periods: 1) First period (September 1999 to February 2000); and 2) Second period (August 2000 to December 2000); empirical treatment was changed from ceftriaxone and/or ceftazidime in the first period to piperacillin/tazobactam in the second. ICU epidemiological and infection control rates, as well as bacterial isolates from upper airways were analyzed. Ceftazidime consumption dropped from 34.83 to 0.85 DDD/1000 patients per day (p=0.004). Piperacillin/tazobactam was originally not available; its consumption reached 157.07 DDD/1000 patients per day in the second period (p=0.0002). Eighty-seven patients and 66 patients were evaluated for upper airway colonization in the first and second periods, respectively. There was a significant decrease in the incidence of K. pneumoniae (p=0.004) and P. mirabilis (p=0.036), restoration of K. pneumoniae susceptibility to cephalosporins (p<0.0001) and reduction of ventilator-associated pneumonia rates (p<0.0001). However, there was an increase in P. aeruginosa incidence (p=0.005) and increases in ceftazidime (p=0.003) and meropenem (p<0.0001) susceptibilities. Changing antimicrobial selective pressure on multi-resistant Gram-negative bacteria helps control ventilator-associated pneumonia and decreases antimicrobial resistance.
由于抗生素耐药菌的出现,强效抗菌药物得以研发,这类耐药菌尤其影响在重症监护病房(ICU)长期住院且先前接受过抗菌药物治疗,特别是第三代头孢菌素治疗的患者。本研究旨在确定ICU患者感染经验性治疗的变化如何影响革兰氏阴性菌的发生率及其对抗菌药物的敏感性,并考察这些变化对医院感染的影响。在一所大学医院的两个时间段内进行了一项前瞻性干预研究:1)第一个时间段(1999年9月至2000年2月);2)第二个时间段(2000年8月至2000年12月);经验性治疗从第一个时间段的头孢曲松和/或头孢他啶改为第二个时间段的哌拉西林/他唑巴坦。分析了ICU的流行病学和感染控制率,以及来自上呼吸道的细菌分离株。头孢他啶的消耗量从每天34.83 DDD/1000患者降至0.85 DDD/1000患者(p = 0.004)。哌拉西林/他唑巴坦最初没有使用;在第二个时间段其消耗量达到每天157.07 DDD/1000患者(p = 0.0002)。第一个时间段和第二个时间段分别对87例患者和66例患者进行了上呼吸道定植评估。肺炎克雷伯菌(p = 0.004)和奇异变形杆菌(p = 0.036)的发生率显著下降,肺炎克雷伯菌对头孢菌素的敏感性恢复(p < 0.0001),呼吸机相关性肺炎发生率降低(p < 0.0001)。然而,铜绿假单胞菌的发生率有所增加(p = 0.005),头孢他啶(p = 0.003)和美罗培南(p < 0.0001)的敏感性增加。改变对多重耐药革兰氏阴性菌的抗菌选择压力有助于控制呼吸机相关性肺炎并降低抗菌药物耐药性。